BioAtla Added to Membership of U.S. Small-Cap Russell 2000® Index
SAN DIEGO, June 26, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the...
Month: June 2023
Ovid Therapeutics Added to Russell 3000® Index
NEW YORK, June 26, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to...
Eyenovia Announces Addition to Russell 2000® and Russell 3000® Indexes
NEW YORK, June 26, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic technology company preparing for the...
Orchestra BioMed Set to Join Russell 3000® and other FTSE Russell Indexes
NEW HOPE, Pa., June 26, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”),...
Assure Holdings Signs Letter of Intent to Purchase Certain Assets of Innovation Neuromonitoring, LLC
Expects to Increase Annual Number of Cases by More than 3,000DENVER, June 26, 2023 (GLOBE NEWSWIRE) -- Assure Holdings Corp....
Portage Biotech Announces First Patient Dosed in Phase 1a Trial of PORT-6 in Select Solid Tumors
WESTPORT, Conn., June 26, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted...
Cidara Therapeutics Added to Russell Microcap® Index
SAN DIEGO, June 26, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed...
LianBio Announces Marketing Approval of CAMZYOS® (mavacamten) in Singapore
SHANGHAI, China and PRINCETON, N.J., June 26, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing...
InspireMD Announces Completion of Enrollment in C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial
Trial designed to support potential U.S. marketing approval of the CGuard™ Prime EPS stent system Study also included first-in-human cases...
Benitec Biopharma Receives FDA Clearance of the IND for BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy
Dosing of the first subject with BB-301 is expected in the second half of 2023, following the rollover of subjects...
Clene Announces Publication of Phase 2 CNM-Au8® Clinical Data for the Treatment of ALS in LANCET’s eClinicalMedicine
Peer-reviewed publication includes data from the CNM-Au8 Phase 2 RESCUE-ALS trial and its open-label-extension, up to 120 weeks of patient...
Sutro Biopharma and Blackstone Announce Royalty Financing Collaboration
- Sutro will receive $140 million upfront and is eligible to receive up to an additional $250 million in future...
Oculis to Host an R&D Retina Day to Showcase Clinical Programs Targeting Diabetic Macular Edema and Other Retina Diseases on Tuesday, July 11, 2023
R&D Retina Day featuring several retina experts will take place from 10:00 AM – 12:00 PM EDT at the Lotte...
Femasys Announces FDA Approval of its IDE for the Pivotal Clinical Trial of FemBloc Permanent Birth Control, a Non-Surgical Alternative for Women
- Pivotal clinical trial to begin in the third quarter of 2023 - ATLANTA, June 26, 2023 (GLOBE NEWSWIRE) --...
Enlivex Announces First Quarter 2023 Financial Results and Provides a Business Update
Enrollment of patients in the Phase I/II evaluating Allocetra™ in combination with chemotherapy in patients with peritoneal metastases from advanced...
AVITA Medical Rejoins the Russell 3000 Index
VALENCIA, Calif., and MELBOURNE, Australia, June 26, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative...
Sernova Announces Positive Updated Interim Phase 1/2 Clinical Data for the Cell Pouch System™ at American Diabetes Association 83rd Scientific Sessions
In the first cohort of the ongoing Phase 1/2 clinical trial, the first 5 patients to complete protocol-defined islet transplants...
POINT Biopharma and AdvanCell to Collaborate in the Development of Lead-212-Labeled Radioligands
POINT’s vertically integrated platform together with AdvanCell’s lead-212 (²¹²Pb) generator technology enables both the development and scaled commercialization of ²¹²Pb-labeled...
OpGen Subsidiary Ares Genetics Successfully Maintains Key Patent under Opposition in Europe
Patent EP 3 332 028 B1 granted by the European Patent Office covers the identification and use of genomic variants...
POINT Biopharma Expands Its Research with Next-Generation Isotopes, Publishing New Preclinical Data at SNMMI’s Annual Congress
Auger electron and beta emitting isotope terbium-161 was paired with POINT’s FAP-targeted PNT6555 ligand and showed robust anti-tumor efficacy, similar...